All In Biotech

NDA 050207 · Carnegie

Eryped

Erythromycin Ethylsuccinate · Oral

Last checked: Nov 19, 2026Latest source record: Apr 23, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1965

Apr 2, 1965

Approved uses

1

Original approval plus efficacy supplements

Registered trials

897

218 Phase 3, 47 recruiting

FAERS reports

609

361 serious, 35 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 16, 2023.

INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ery-Ped and other antibacterial drugs, Ery-Ped should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ery-Ped is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during...

Mechanism: Mechanism of Action Erythromycin acts by inhibition of protein synthesis by binding 50 S ribosomal subunits of susceptible organisms. It does not affect nucleic acid synthesis. Antagonism has been demonstrated in vitro between erythromycin and clindamycin, lincomycin, and chloramphenicol.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 2, 1965 Original approval
3 products under this application
  • ERYPED · ERYTHROMYCIN ETHYLSUCCINATE EQ 200MG BASE/5ML · GRANULE, ORAL · Prescription · TE AB
  • E.E.S. · ERYTHROMYCIN ETHYLSUCCINATE EQ 200MG BASE/5ML · GRANULE, ORAL · Prescription · TE AB
  • ERYPED · ERYTHROMYCIN ETHYLSUCCINATE EQ 400MG BASE/5ML · GRANULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Erythromycin Ethylsuccinate" as an intervention, any sponsor and status, largest first.

All 897 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug hypersensitivity72
  • vomiting45
  • nausea41
  • diarrhoea36
  • off label use34
  • rash24
  • dyspnoea23
  • hypersensitivity22
  • product use in unapproved indication22
  • abdominal pain21
  • pruritus21
  • urticaria17

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200413
200511
20068
20075
200815
200913
201030
201126
201217
201335
201421
201517
201645
201737
201846
201953
202032
202130
202213
202331
202445
202545
202621

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 72 on PubMed

Sponsor: Carnegie · Also marketed as E.E.S.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.